B22 – Funding Pathways for New Technology with an Identity Problem – Is it a drug or a device or a …? What is slipping between the PBAC/MSAC crack?

The current plethora of funding pathways and the resulting funding silos, risks the creation of perverse incentives, that is, treatment decisions based on funding availability rather than clinical effectiveness.  Advances in medical technology have also led to the availability of products that don’t fit the traditional drug or device definition. This session will examine the challenge of how to avoid the down side of funding silos while maintaining fit-for-purpose funding pathways that recognise the crucial differences between drugs and devices and other technology that are probably neither.